Diverse Biotech Chooses Doylestown, Pennsylvania For U.S. Headquarters
A prominent incubator for small growing life sciences companies, the Pennsylvania Biotechnology Center contains a wealth of resources and a core support group of scientists and executives motivated to work collaboratively with their commercial colleagues on common research themes.
Diverse Biotech said its focus is on discovering and developing novel therapeutics, utilizing cannabidiol as a core component and combining it through advanced conjugate chemistry with other targeted medicines to develop new chemical entities that are theoretically more efficacious and less toxic. Our initial focus is on hard-to-treat oncologic disorders including basal cell carcinoma and other Dermatology related cancers, Pancreatic cancer and Glioblastoma, where targeted therapies have proven largely unsuccessful thus far and there is significant unmet need.
According to company officials, in addition, Diverse Biotech continues to identify and evaluate additional locations to relocate its Miami Laboratory facilities.
"We are very happy with our strategic decision to establish our headquarters at the Pennsylvania Biotechnology Center, it is truly a tremendous scientific community and a perfect place for Diverse Biotech to continue its growth journey," said Stella Vnook, Diverse Biotech's CEO.
Novartis’ French-Based Subsidiary Advanced Accelerator Applications Plans Cancer Drug Production Campus in Indianapolis, Indiana
Plant Plus Brings Operations & Distribution Center to Edmonton, Alberta International Airport
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Finding Talent in a Time of Economic Change
Mid-size Markets Competing for Business and Winning
Hitting the Reset Button: How to Pivot the Perception of Economic Development
Innovation in America Reaches New Heights
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019